Iovance Biotherapeutics, Inc. financial data

Symbol
IOVA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, 4 Th Floor, San Carlos, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Lion Biotechnologies, Inc. (to 6/5/2017), Genesis Biopharma, Inc (to 9/23/2013), FREIGHT MANAGEMENT CORP (to 3/8/2010)
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 413 % -16.6%
Quick Ratio 23.3 %
Debt-to-equity 28.5 % +1.39%
Return On Equity -58.4 % +18.4%
Return On Assets -45.5 % +18.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 305M shares +19.1%
Common Stock, Shares, Outstanding 305M shares +19.1%
Entity Public Float 1.4B USD -12.5%
Common Stock, Value, Issued 13K USD +18.2%
Weighted Average Number of Shares Outstanding, Basic 303K shares +23.4%
Weighted Average Number of Shares Outstanding, Diluted 303K shares +23.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 58.6M USD +12385%
Cost of Revenue 39.8M USD +818%
Research and Development Expense 298M USD -11.7%
General and Administrative Expense 140M USD +35.7%
Costs and Expenses 521M USD +24.2%
Operating Income (Loss) -430M USD +3.67%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -416M USD +26%
Income Tax Expense (Benefit) -6.15M USD -22.3%
Net Income (Loss) Attributable to Parent -410M USD +5.31%
Earnings Per Share, Basic -1.5 USD/shares +27.9%
Earnings Per Share, Diluted -1.5 USD/shares +27.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 164M USD -38.7%
Accounts Receivable, after Allowance for Credit Loss, Current 55.8M USD
Inventory, Net 38.6M USD +320%
Assets, Current 499M USD +30.3%
Property, Plant and Equipment, Net 113M USD -0.55%
Operating Lease, Right-of-Use Asset 66.7M USD +0.72%
Other Assets, Noncurrent 280K USD -0.71%
Assets 991M USD +16.3%
Accounts Payable, Current 31.7M USD +64.4%
Accrued Liabilities, Current 74.8M USD +22.2%
Liabilities, Current 118M USD +29.8%
Deferred Income Tax Liabilities, Net 32.2M USD +75.6%
Operating Lease, Liability, Noncurrent 66.4M USD -2.38%
Liabilities 218M USD +22.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 16.2M USD
Retained Earnings (Accumulated Deficit) -2.31B USD -21.6%
Stockholders' Equity Attributable to Parent 773M USD +14.8%
Liabilities and Equity 991M USD +16.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -122M USD -22.5%
Net Cash Provided by (Used in) Financing Activities 194M USD -25%
Net Cash Provided by (Used in) Investing Activities -112M USD -173%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 305M shares +19.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -40.7M USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 171M USD -49%
Deferred Tax Assets, Valuation Allowance 447M USD +27.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 464M USD +26.4%
Operating Lease, Liability 77.9M USD -0.68%
Depreciation 10.3M USD +129%
Payments to Acquire Property, Plant, and Equipment 4.17M USD -26.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -385M USD +12.6%
Lessee, Operating Lease, Liability, to be Paid 123M USD -2.28%
Property, Plant and Equipment, Gross 149M USD +7.93%
Operating Lease, Liability, Current 11.6M USD +10.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.99M USD -4.03%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.9M USD +30.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -1.41M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 45.5M USD -4.89%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.19M USD +2.47%
Deferred Tax Assets, Operating Loss Carryforwards 256M USD +13.2%
Unrecognized Tax Benefits 26.1M USD +20.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.39M USD +2.48%
Operating Lease, Payments 17.3M USD +3.62%
Additional Paid in Capital 3.06B USD +18.8%
Amortization of Intangible Assets 19.6M USD +37.5%
Depreciation, Depletion and Amortization 12M USD +5.32%
Deferred Tax Assets, Net of Valuation Allowance 17.6M USD +2.91%